Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

International Immuno-Oncology Biomarker Working Group

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting.

Original languageEnglish (US)
Article number15
Journalnpj Breast Cancer
Volume6
Issue number1
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials'. Together they form a unique fingerprint.

  • Cite this